G2 (1) Metabolic syndrome

More documents

Recommendations

Info

International Diabetes Federation (IDF) ConsensusDefinition 2005Central ObesityWaist circumference– ethnicity specific*– for Europids: Male > 94 cmFemale > 80 cmplus any two of the following 4:Raised triglyceridesReduced HDL cholesterolRaised blood pressureRaised fasting plasmaglucose> 150 mg/dL (1.7 mmol/L)or specific treatment for this lipid abnormality< 40 mg/dL (1.03 mmol/L) in males< 50 mg/dL (1.29 mmol/L) in femalesor specific treatment for this lipid abnormalitySystolic : > 130 mmHg orDiastolic: > 85 mmHg orTreatment of previously diagnosed hypertensionFasting plasma glucose > 100 mg/dL (5.6 mmol/L) orPreviously diagnosed type 2 diabetesIf above 5.6 mmol/L or 100 mg/dL, OGTT is stronglyrecommended but is not necessary to define presence of the<strong>syndrome</strong>.
International Diabetes Federation (IDF)Definition• Modified ATPIII definition– Fasting Glucose > 100mg/dl (5.6 mmol/l)– Adjusted waist circumference based on ethnicity(i.e. Asians with lower waist circumferencethreshold than pacific islanders)
Page 2 and 3: OBJECTIVES• Definition and diagno
Page 4 and 5: Diagnosis• The National Cholester
Page 6 and 7: Third Report of the Expert Panel on
Page 10 and 11: WHO definition of IRS, 1999AT LEAST
Page 12 and 13: DEFINITIONS OF METABOLIC SYNDROMERi
Page 16 and 17: • Adipocyte derives hormones call
Page 18 and 19: Clinical importance of MSPresence o
Page 20 and 21: Impact of the Metabolic Syndrome on
Page 22 and 23: Metabolic Syndrome: Total and CV Mo
Page 26 and 27: HARMONIZING THE METABOLIC SYNDROME.
Page 28 and 29: SOCIODEMOGRAPHIC CHARACTERISTICS OF
Page 30 and 31: Prevalence (%)PREVALENCE OF METABOL
Page 32 and 33: Prevalence (%)PREVALENCE OF METABOL
Page 34 and 35: MetS - where is Malaysiacompared to
Page 36 and 37: Prevalence of MetS in other populat
Page 38 and 39: Status of Diabetes Mellitus inMalay
Page 42 and 43: Cardiovascular Risk Reducing Treatm
Page 44 and 45: LIFE STYLE MODIFICATIONS WORKS• P
Page 46 and 47: MET-hours/weekHbA1c (%): placebo: M
Page 48: LIPIDSRisk FactorsLDL-cholesterolRe
Page 52 and 53: Cardiovascular Risk Reducing Treatm
Page 54 and 55: CONCLUSIONS• Definition and diagn

G2 (1) Metabolic syndrome

Create successful ePaper yourself

Delete template?

Save as template?